Boston Scientific Corporation (BSX) Competitors & Peers
The 5 companies closest to Boston Scientific Corporation on the factors that matter — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| ABT | Competitor | $109.50 | P/E 35.6RSI 70Cap 190.7 B |
| SYK | Competitor | $347.18 | P/E 35.9RSI 59Cap 133.1 B |
| MDT | Competitor | $89.91 | P/E 24.1RSI 69Cap 114.9 B |
| EW | Competitor | $93.17 | P/E 55.5RSI 67Cap 53.7 B |
| GEHC | Peer | $72.36 | P/E 16.8RSI 67Cap 33.1 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- SRDXPartner
Surmodics licenses its advanced hydrophilic surface coatings and drug-delivery technologies for intravascular devices to Boston Scientific.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- PENPartner
Penumbra entered into a definitive agreement to be acquired by Boston Scientific for approximately $14.5 billion.
Model-inferred, unverified — treat as a lead, not evidence - MIRUSPartner
Boston Scientific announced a $1.5 billion strategic investment for an approximately 34% equity stake in MiRus LLC and an option to acquire its TAVR business.
Model-inferred, unverified — treat as a lead, not evidence - AXNXPartner
Boston Scientific completed the acquisition of Axonics, Inc. for approximately $3.7 billion, adding sacral neuromodulation systems to its Urology business.
Model-inferred, unverified — treat as a lead, not evidence - SILKPartner
Boston Scientific completed the acquisition of Silk Road Medical for approximately $1.16 billion to add Transcarotid Artery Revascularization (TCAR) systems.
Model-inferred, unverified — treat as a lead, not evidence - MCKSupplier
McKesson serves as a major wholesale distributor of Boston Scientific's medical devices to hospitals and clinics.
Model-inferred, unverified — treat as a lead, not evidence - CAHSupplier
Cardinal Health distributes Boston Scientific's surgical, cardiovascular, and urological products to healthcare providers.
Model-inferred, unverified — treat as a lead, not evidence - SYKCompetitor
Stryker and Boston Scientific compete in endoscopy, structural heart, and now directly in vascular intervention following SYK's Inari acquisition.
Model-inferred, unverified — treat as a lead, not evidence - CORSupplier
Cencora (AmerisourceBergen) distributes Boston Scientific's medical technologies and clinical supplies globally.
Model-inferred, unverified — treat as a lead, not evidence - MDTCompetitor
Boston Scientific is a primary competitor in cardiac rhythm, neuromodulation, and vascular intervention.
Model-inferred, unverified — treat as a lead, not evidence - EWCompetitor
Boston Scientific competes with Edwards in TAVR systems (Boston Acurate vs Edwards SAPIEN) and left atrial appendage occlusion devices.
Model-inferred, unverified — treat as a lead, not evidence - ABTCompetitor
Boston Scientific competes with Abbott in cardiac rhythm management, electrophysiology, and structural heart (e.g., WATCHMAN vs Amulet).
Model-inferred, unverified — treat as a lead, not evidence - SRDXSupplier
Surmodics supplies medical device coatings and license-based surface technologies to Boston Scientific for their catheter-based products.
Model-inferred, unverified — treat as a lead, not evidence - HCASupplier
HCA uses BSX cardiovascular + neuromod.
Model-inferred, unverified — treat as a lead, not evidence